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Abstract
Background: Postmenopausal hormone-replacement therapy (HRT) increases breast-cancer risk.
The influence of HRT on the biology of the primary tumor, however, is not well understood.
Methods: We obtained breast-cancer gene expression profiles using Affymetrix human genome
U133A arrays. We examined the relationship between HRT-regulated gene profiles, tumor
characteristics, and recurrence-free survival in 72 postmenopausal women.
Results: HRT use in patients with estrogen receptor (ER) protein positive tumors (n = 72) was
associated with an altered regulation of 276 genes. Expression profiles based on these genes
clustered ER-positive tumors into two molecular subclasses, one of which was associated with HRT
use and had significantly better recurrence free survival despite lower ER levels. A comparison with
external data suggested that gene regulation in tumors associated with HRT was negatively
correlated with gene regulation induced by short-term estrogen exposure, but positively
correlated with the effect of tamoxifen.
Conclusion: Our findings suggest that post-menopausal HRT use is associated with a distinct gene
expression profile related to better recurrence-free survival and lower ER protein levels.
Tentatively, HRT-associated gene expression in tumors resembles the effect of tamoxifen exposure
on MCF-7 cells.
Background
There is convincing evidence that users of HRT are at
increased risk of breast cancer, that risk increases with
duration of use, and that the risk is substantially greater
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for combined estrogen-progestin than for estrogen-only
HRT [1-4]. The impact of HRT use on breast-cancer prog-
nosis and clinical characteristics is, however, not well
understood. Results from a large randomized clinical trial,
the Women's Health Initiative, indicate a poorer outlook
in users of combined estrogen-progestin therapy, repre-
sented by a larger proportion of tumors with lymph-node
metastases and by differentiated tumors [3,4]. In contrast,
observational studies have repeatedly reported less malig-
nant clinical features as well as improved prognosis in
HRT users [5-8]. This finding may be due to biases such as
closer medical surveillance and reduced sensitivity and
specificity of mammography screening in women on
HRT, and the exclusion of women with preclinical breast-
cancer lesions before initiation of hormone therapy [5,8].
The effect of estrogen is mediated through its receptors in
concert with co-activators and co-repressors [9-12].
Through transcriptional mechanisms involving the ER,
estrogens regulate proliferation and cell cycle progression.
In addition, estrogens have also been postulated to influ-
ence the regulation of cell death and genomic instability
of cells [12].
Expression microarrays have been employed in the analy-
sis of breast cancers and can provide better prognostic
information compared with standard clinical and patho-
logical parameters [13-17]. Microarray analyses appear to
be able to discriminate sporadic versus hereditary breast
cancer [18] and to identify array profiles that are strongly
associated with ER status [13,14,16]. In vitro studies have
confirmed consistent effects of exogenous estrogens on
gene expression in human cell lines [19,20] and in ani-
mals [21].
In this study, we aimed to compare gene expression of
breast cancers in HRT users and non-users and to correlate
the expression pattern to recurrence-free survival. We fur-
ther investigated whether the gene expression pattern-sur-
vival relation would hold in an independent cohort of
patients with breast cancer. Finally, we explored the possi-
ble mechanism behind such a link by comparison with
external gene-expression data from an estrogen- and
tamoxifen-treated cell line.
Methods
Study populations
All women (n = 524) operated on for breast cancer at
Karolinska Hospital, Stockholm, Sweden, from 1 January
1994 through 31 December 1996, were included in the
study. Patients were excluded because of: lack of frozen
tumor tissue (n = 231), insufficient quality of tumor mate-
rial (n = 103), actively refusing consent (n = 6), or emigra-
tion (n = 7). Another 18 patients were excluded for
clinical reasons (neoadjuvant chemotherapy, in situ can-
cer, or recurrence after surgery within 1 month). Of the
159 remaining patients, 98 were postmenopausal. We
obtained information on use of HRT and other breast-
cancer risk factors from the case records. Users were
defined as patients on HRT at time of referral to the Karo-
linska Hospital. Non-users were those actively stating no
current or previous use of HRT. Ten patients who were
former users of HRT were excluded, leaving 88 patients in
the study, of which 32 received HRT at time of diagnosis
and 56 were non-users. Of the 32 users, 20 used a com-
bined estrogen and progesterone regimen, 11 used estro-
gen only, and for one patient, detailed information was
unavailable. The mean duration of use was 7.2 years and
38% had used hormones for more than 5 years. The
patients were followed for at least 8 years after diagnosis,
until time of recurrence or death, whichever event
occurred first. This cohort will be referred to as the "study
cohort".
Data from 131 postmenopausal women surgically treated
for ER-positive breast cancer in 1987–89 at the University
Hospital of Uppsala, Sweden were used for validation
[22]. Gene expression data were obtained in the same way
as for the study cohort. Hereafter we refer to this cohort as
the "validation cohort". Twelve-year follow-up data, clin-
ical stage, Elston grade, ER and progesterone receptor (PR)
status, and information about adjuvant hormonal therapy
was available for these patients, but there was no informa-
tion about HRT use.
The institutional review boards at Karolinska Institutet
and Hospital, respectively, approved the microarray
expression studies.
Molecular analyses 
ER and progesterone receptor (PR) status was measured in
cytosol by enzyme immunoassay [22]. Values above 0.5
fmol/g of cytosol protein were considered to indicate pos-
itive receptor-protein expression. For some analyses, we
used the absolute measurement of the receptor protein,
measured in fmol/g of cytosol protein. Elston grade was
blindly reassessed by one of the authors (HN) using pre-
defined criteria [23].
RNA was prepared using RNeasy spin column kit (Qiagen,
Valencia, CA, USA). Frozen tumors were cut into minute
pieces and homogenized for 40 seconds in RNeasy Lysis
Buffer (RLT). Proteinase K was added, [24] and the sam-
ples were incubated for 10 minutes at 55°C, followed by
centrifugation and the addition of ethanol. After the trans-
fer onto RNeasy columns, DNase was added to increase
RNA quality. RNA quality was assessed using an Agilent
2100 bioanalyzer (Agilent Technologies, Rockville, MD).
The material was stored at -70°C. The amount of RNA for
each probe preparation varied between 2 and 5 μg. First-BMC Medicine 2006, 4:16 http://www.biomedcentral.com/1741-7015/4/16
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strand cDNA synthesis was generated by using a T7-linked
oligo-dT primer, followed by second-strand synthesis. The
in vitro transcription reactions were performed in batches
to generate biotinylated cRNA targets, which were subse-
quently chemically fragmented at 95°C for 35 minutes.
Ten μg of the fragmented, biotinylated cRNA was hybrid-
ised at 45°C for 16 hours to an Affymetrix high-density
oligonucleotide array (human genome U133 A Genchip®).
These were then washed and stained with streptavidin-
phycoerythrin (10 μg/ml). Signal amplification was
achieved using a biotinylated anti-streptavidin antibody.
The scanned images were inspected for the presence of
artifacts. In case of defects, the hybridisation procedure
was repeated. Expression values and detection calls were
computed from raw data following the procedures out-
lined for the Affymetrix MAS 5.0 analysis software. Global
mean normalization of the MAS 5.0 expression was used
to reduce differences in chip intensity [25].
A sample was either re-labeled, and the hybridization
repeated, or excluded from further analysis if a scaling fac-
tor >4 was necessary, <30% present calls were found, or
the squared multiple correlation coefficient of the expres-
sion data on the array to all other arrays was <0.6 [26].
Expression data for 22,283 probe sets and 88 breast pri-
mary tumors were used. Probe sets which were not
detected in at least 50% of the tumors were excluded,
which led to a final 11,295 probe sets, representing 8113
genes for analysis. The expression data has been deposited
at the GEO repository under the accession number
GSE1456.
Comparisons with cell-line experiments
In the cell-line experiments by Finlin et al [27], estrogen-
deprived MCF-7 cells were cultured in 10-8 M β-17-estra-
diol for 4, 8, and 24 h. The tamoxifen-treated samples
were exposed to either 1 or 6 μM of tamoxifen for 48 h.
Statistical analyses
We computed gene-wise test statistics ti to measure the
strength of the relationship between the expression of
gene gi and the clinical variable of interest. For the associ-
ation with HRT use, we calculated the two-sample Welch
t statistic. For association with age, we used the Spearman
rank correlation coefficient. Larger absolute values of
either statistic correspond to a stronger association with
HRT status and age, respectively. Positive values of the sta-
tistic indicate that a gene is over-expressed in HRT users,
and vice versa.
The cut-off for deciding that a gene gi is significantly dif-
ferentially expressed is not based on the usual p values.
Instead, we select genes based on their local false discov-
ery rate (FDR) as described in [26]. The quantity fdri asso-
ciated with gene gi  specifies the proportion of false-
positive results that can be expected among genes that
have the same test statistic ti. Equivalently, we can inter-
pret 1 minus fdri as the probability that gene gi is truly
associated with the clinical variable of interest. The genes
under study were assumed to be a mixture of differentially
and non-differentially expressed genes, where the distri-
bution of t statistics for non-differentially expressed genes
can be inferred from random permutations of the data.
Initially, all genes with local FDR <0.2 were selected as
candidate genes for discriminating between HRT users
and non-users. This liberal cut-off point was chosen
because the aim of the present study was not to identify
specific genes, but rather patterns of expression. A high
cut-off level for gene selection would be more likely to
identify genes strongly linked to exposure to HRT, but not
comprehensive biologically relevant patterns.
Preliminary analysis of the clinical data indicated that
HRT use was associated with age, and thus that age is a
possible confounding factor for the relationship between
gene expression and HRT use (Table 1). We therefore
removed HRT-associated genes that were significantly cor-
related with age in the reference group of ER-positive non-
HRT users (n = 50). The significance cut-off point was
again based on the local FDR estimate, here for the Spear-
man rank correlation coefficient. Genes with local FDR
<0.4 for age were excluded from the list of HRT candidate
genes.
The 72 patients with ER-positive tumors in the study
cohort were hierarchically clustered based on the age-
adjusted HRT candidate gene list. We used average linkage
and Euclidean distances; each gene was robustly standard-
ized by subtracting the median and dividing by the inter-
quartile range of expression prior to clustering. We used
consensus clustering to assess the stability of the resulting
grouping of samples and found it to be robust (see addi-
tional file 1).
We used Kaplan-Meier estimates with the log-rank test for
establishing the univariate association between cluster
membership and recurrence-free survival. We modeled
multivariate survival using the Cox proportional hazards
model. Hazard ratios and their 95% confidence intervals
were computed from the Wald test statistics; the p value
for each variable is based on the likelihood ratio test com-
paring the full model and the model without the tested
variable, using the asymptotic χ2 distribution of the likeli-
hood ratio. The multivariate models were adjusted for
age, Elston grade, tumor size, lymph node status, PR sta-
tus, and HRT use.BMC Medicine 2006, 4:16 http://www.biomedcentral.com/1741-7015/4/16
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For validation, we used a simple supervised clustering
scheme, in which groups identified in the study cohort
through hierarchical clustering were characterized via
their centroids (i.e. by averaging gene expression for each
group). All patients in the validation cohort were assigned
to the centroid with the smallest Euclidean distance for
the same robustly standardized genes.
For comparison with MCF-7 cells, we chose genes that
were found to be responsive to both estrogen and
tamoxifen, based on the experimental data described pre-
viously and deposited in the Stanford Microarray Data-
base [27]. Cells were treated with either 10 nM 17β-
estradiol and harvested at 4, 8, and 24 hours following
treatment, or with 1 and 6 μM of tamoxifen and harvested
after 48 hours. Genes chosen showed a consistent mini-
mum fold change for estradiol exposure and an inverse
fold change for tamoxifen exposure, when compared with
untreated control groups (see additional file 1). Response
to hormone treatment and sensitivity to tamoxifen is a
standard criterion for defining ER-regulated genes, and
while it will not capture all anti-estrogen-responsive genes
[28], we were specifically interested in genes that can be
expected to be regulated by the presence of both HRT and
tamoxifen. For genes that fulfilled this criterion and were
associated with HRT use, we computed fold changes
between HRT users and non-users, and compared them
with the fold changes found in the experimental data.
Results
Non-HRT users were older than HRT users at time of diag-
nosis (p = 0.001; Table 1), but no difference in average
tumor size (p = 0.39) or proportion of patients with
lymph-node metastasis (p = 1.0) was evident. Signifi-
cantly more ER negative tumors were seen in HRT users
(31% versus 11%, p = 0.02). No difference in progester-
one-receptor status, recurrence-free survival (defined as
lack of distant metastases or death within 5 years of diag-
nosis) or Elston grade was seen between users and non-
users of HRT (Table 1). Comparisons using only patients
with ER-positive tumors yielded similar results.
A preliminary study of the distribution of t statistics com-
paring gene expression between HRT users and non-users
for all 88 patients indicated that the observed differences
are almost exclusively due to the differences observed in
the ER-positive tumors, whereas the ER-negative tumors
contribute little or no information on differential expres-
Table 1: Characteristics of the HRT and non-HRT users in the full study cohort (n = 88) and for estrogen-receptor-positive patients
(n = 72): Characteristics of the HRT and non-HRT users in the study population
No HRT HRT
All n = 56 ER+ n = 50 All n = 32 ER+ n = 22 P valuea
Age at breast cancer diagnosisb 67.2 ± 11.0 60.1 ± 8.6 0.001
67.8 ± 10.8 59.9 ± 8.7 0.004
Tumor size, mmb 23.0 ± 12.4 26.1 ± 17.1 0.39
23.4 ± 12.8 26.2 ± 18.4 0.47
Affected lymph nodes 40% 21/52 39% 12/31 1.00
41% 19/46 43% 9/21 1.00
Estrogen receptor-negative tumorsc 11% 6/56 31% 10/32 0.02
N/A N/A N/A
Estrogen receptor-protein, fmol/gd 1.8 ± 2.1 0.8 ± 1.5 0.01
2.0 ± 2.2 1.2 ± 1.8 0.11
Progesterone receptor-negative tumorsc 27% 15/56 41% 13/32 0.23
18% 9/50 23% 5/22 0.75
Recurrence-free survivale 71% 40/56 84% 27/32 0.20
72% 36/50 86% 19/22 0.24
Elston grade 0.61
0.27
Grade I 18% 9/51 23% 7/30 -
20% 9/45 33% 7/21 -
Grade II 45% 23/51 50% 15/30 -
49% 22/45 52% 11/21 -
Grade III 37% 19/51 27% 8/30 -
31% 14/45 14% 3/21 -
Values for the ER+ cohort are shown in italics. Means and percentages are shown in bold, standard deviations and counts in plain font. a Calculated 
via a t-test for age, size, and estrogen-receptor protein, via Fisher's exact test otherwise. b Mean plus/minus standard deviation. c Measured through 
an immunoassay in which monoclonal antibodies react with the receptor protein in cytosol from tumor homogenates, >0.5 fmol receptor protein/
g of cytosol protein was considered as receptor positive. d The immunoassay measurement as described in c above.e Measured as death or distant 
metastasis within 5 years of diagnosis.BMC Medicine 2006, 4:16 http://www.biomedcentral.com/1741-7015/4/16
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sion (see supplementary Figure 1 and the associated dis-
cussion in additional file 1). As the difference in
expression profiles between HRT-users and non-users was
confined to ER-positive tumors, we limited all further
analysis to this group (n = 72).
Among the 72 patients with ER-positive tumors, 22 were
HRT users and 3 (14%) experienced recurrence or death
due to breast cancer within 5 years of diagnosis. Recur-
rence among non-users was seen in 14 patients (28%; p =
0.24).
We observed 331 genes to be differentially expressed
between HRT users and non-users, with a local FDR ≤ 0.2,
of which 54% were down-regulated in HRT users. We also
found 580 genes that were correlated with age in non-
users of HRT with a local FDR ≤ 0.4. We removed the 55
genes that were on both lists, which yielded an age-
adjusted HRT associated gene list of 276 genes (The anno-
tated list of genes can be found in additional file 2).
Molecular classification of patients based on HRT- 
associated genes
The 72 ER-positive cancers were grouped using hierarchi-
cal clustering on the expression profiles of the 276 genes
(Figure 1). Each column corresponds to a patient labeled
according to HRT use, recurrence or death within 5 years,
Elston grade 3, lymph node metastasis, and ER protein
levels. Two distinct clusters emerged. Obviously, these
clusters differed significantly in the proportion of patients
receiving HRT (100% in the HRT-associated cluster versus
13% in the non-HRT-associated cluster, p < 10E-9). There
was, however, no significant difference with regard to type
and duration of HRT use between the groups. In the HRT-
associated cluster, 11 (77%) out of 13 patients used com-
bined therapy with estrogen and progesterone, and the
average duration of HRT use was 6.2 years. The corre-
sponding figures in the non-HRT associated cluster were 4
(50%) out of 8 HRT users (p = 0.34) and 8.8 years (p =
0.42), respectively.
The clusters differed significantly with regard to ER pro-
tein levels (p = 0.02), but not Elston grade (p = 0.67) or
lymph node status (p = 1.00). All patients in the HRT-
associated cluster were recurrence free 5 years after diag-
nosis and thus, had a significantly better recurrence-free
survival (p = 0.03), even after adjusting for Elston grade,
tumour size, lymph node status, PR status, HRT use, and
age in the multivariate model (p = 0.001, see supplemen-
tary Table 1 in additional file 1).
Validation of molecular classification
In the validation cohort, the clustering split the 131
tumors into two groups of 68 non-HRT-like and 63 HRT-
like expression profiles (Figure 2). Each column corre-
sponds to a patient labeled according to recurrence or
death within 5 years, Elston grade 3, lymph-node metas-
tasis, and ER protein levels. As no HRT information was
available for the validation cohort, the data could only be
used to confirm the prognostic potential of the clustering.
Tumors with HRT-associated profiles had better recur-
rence-free survival (p = 0.02), lower Elston grade (p =
0.02), lower protein levels of ER (p = 0.02), and were
more often node-negative. When only patients treated
with adjuvant tamoxifen (n = 51) were included, we
found patients in the HRT-associated cluster to have a sig-
nificantly better survival (p = 0.04), even after adjusting
for the effects of Elston grade, lymph node status, PR sta-
tus, tumor size, and age at time of diagnosis in the multi-
variate model (p = 0.001, see supplementary Table 1 in
additional file 1). For patients not receiving adjuvant hor-
monal therapy (n = 80), the the survival difference
between the clusters was still significant (p = 0.03), even
after adjustment for potential confounders (p = 0.02), but
the relationship between the clusters was reversed;
patients in the HRT-associated cluster did worse, indicat-
ing that tamoxifen influenced the apparent beneficial
prognostic effect of HRT-associated gene expression. This
effect was not seen in the study cohort, probably
explained by the small number of patients (n = 7; 8%) left
without adjuvant hormonal therapy.
Figure 3 shows the survival (Kaplan-Meier curves, i.e. no
adjustment) of the patient cohorts with the respective
gene expression signatures. While patients with the HRT-
like signature did better in the overall validation cohort
(Figure 3b), the main benefit was experienced by those
receiving adjuvant hormonal therapy (Figure 3d),
whereas the small benefit for those treated only with sur-
gery and radiation therapy was convincingly non-signifi-
cant (Figure 3c).
Comparison of expression-fold changes with cell-line 
results
Of the 276 genes associated with HRT use, 84 unique
genes corresponding to 96 probe sets were found to be
estrogen- and tamoxifen-responsive in the experimental
data described in [27] (see additional file 3). In order to
compare the regulatory effect of HRT in breast cancer, and
estrogen and tamoxifen in cell lines, we grouped genes
into those that are down-regulated (n = 54) and up-regu-
lated (n = 30) in HRT users. Figure 4 summarizes the fold
changes induced in these two groups of genes by estrogen
and tamoxifen. Fold changes are shown on a log2 scale, so
the dashed line at zero corresponds to no differential
expression, whereas positive values indicate upregulation
in treated cells and negative values indicate downregula-
tion in treated cells compared with untreated controls.
Figures 4a and 4b indicate a negative correlation between
the effects of HRT and estrogen; the genes that are down-BMC Medicine 2006, 4:16 http://www.biomedcentral.com/1741-7015/4/16
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Unsupervised clustering of the study cohort Figure 1
Unsupervised clustering of the study cohort. Hierarchical clustering using 276 HRT associated genes in ER positive 
tumors (n = 72). Each column corresponds to a patient, each row to a gene; expression level is indicated on a color scheme 
from green/low to red/high. Patients are labeled according to HRT use, recurrence-free survival (= recurrence, defined as dis-
tant metastases or death within 5 years of diagnosis), Elston grade 3, lymph node status, and ER level measured on the protein 
level. Gray symbols indicate missing values.
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Supervised clustering of the validation cohort Figure 2
Supervised clustering of the validation cohort. Supervised clustering of 131 ER-positive postmenopausal Uppsala 
patients using the 276 genes identified in the Stockholm material, shown by row and in the same order as in Figure 1. Each col-
umn corresponds to a patient labeled according to survival (= recurrence; defined as distant metastases or death within 5 years 
of diagnosis), Elston grade 3, and lymph node status, where gray symbols indicate missing values. ER protein values were trun-
cated at 40 for display purposes.
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Survival curves for study and validation cohort, by expression profile cluster Figure 3
Survival curves for study and validation cohort, by expression profile cluster. Kaplan-Meier curves comparing recur-
rence-free survival (defined as no death and no distant metastasis) for patients with HRT-like expression profiles (solid line) 
and patients with non-HRT-like expression lines (dashed lines). Follow-up was 8 years for the study cohort and 12 years for 
the validation cohort. Number of events/number of patients are shown for each group next to the corresponding curve. The p 
values are calculated via the log-rank test. Panels (a) and (b) show the full study and validation cohorts, respectively, as 
described in the paper; the treated and untreated sub-cohorts of the validation cohort refer to adjuvant hormonal therapy, as 
all patients received surgery and radiotherapy.
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regulated by HRT are predominantly upregulated by estro-
gen, and vice versa. In contrast, we saw positive
correlation between the effects of HRT and low doses of
tamoxifen (Figure 4c); Figure 4d shows a similar,
although weaker relationship for high doses of tamoxifen.
Comparison with cell line experiments Figure 4
Comparison with cell line experiments. Fold changes induced by estrogen and tamoxifen treated MCF-7 cell lines for 
unique genes that are down-regulated (n = 54) or up-regulated (n = 30) by HRT in breast cancer patients. The fold changes are 
shown on the log2 scale, so the dashed line at zero corresponds to no differential expression, positive values correspond to up-
regulation in treated cells, and negative values correspond to down-regulation in treated cells compared with untreated con-
trol cells (see additional file 1 on fold change calculation and gene matching).
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Discussion
We have shown that a gene expression profile in ER-posi-
tive HRT users, based on 276 genes, is significantly associ-
ated with better survival, despite being linked to lower
levels of the ER protein. HRT use by itself could not be
used as a predictor of outcome. The gene-expression pro-
file remained significantly associated with survival even
after adjusting for Elston grade, lymph-node status, PR
status, tumor size, treatment, HRT use, and age. The asso-
ciation between expression profile and survival was vali-
dated in a separate cohort of adjuvantly treated patients
with breast cancer. On a more speculative note, a compar-
ison with cell line data indicated that long-term use of
HRT may exert a tamoxifen-like effect on ER-positive
breast-cancer cells. The majority of HRT users exhibiting
an HRT-like gene expression pattern used a combined
estrogen+progesteron regimen, however, owing to lack of
power, we are unable to attach any significance to this
finding.
Our results indicate that HRT use appears to alter only the
expression profiles of ER-positive breast cancers. This
finding is consistent with known biological and clinical
observations, given that only ER-positive cells are
expected to preferentially respond to estrogen exposure.
In agreement with our findings, the Tamoxifen Chemo-
prevention Trial [31] showed reduction of breast-cancer
risk only for ER-positive tumors, further supporting the
fundamental specificity of the in vivo ligand-estrogen
receptor effects.
In the validation cohort, the superior outcome of the
HRT-associated cluster was apparent only in those
patients receiving adjuvant tamoxifen, suggesting that we
can identify patients who preferentially benefit from
tamoxifen therapy. This observation is made more note-
worthy by the fact that these patients had lower ER protein
levels and would normally be considered less likely to
respond to tamoxifen. Thus, the expression pattern of a
tumor may add predictive value for the response to hor-
monal treatment to the ER protein levels.
Paradoxically, although HRT is considered an ER agonist,
the expression profile induced after prolonged use of HRT
was opposite to that of estradiol and consistent with
tamoxifen effects (Figure 4) in MCF-7 cells. The exact ram-
ifications of this observation are not clear, but it is known
that very high doses of estradiol (e.g. diethylstilbestrol)
induce clinical tumor regression, similar to anti-estrogens
[32]. Intriguingly, recent experimental evidence suggests
that estradiol induces apoptosis in breast-cancer cells that
have developed resistance to tamoxifen therapy [33,34].
The idea that tamoxifen therapy following estradiol stim-
ulation may have a similar effect as estrogen following
tamoxifen on cell death is interesting from a therapeutic
point of view, but requires further investigation.
Earlier studies have found HRT-use to be associated with
lower mortality [35,36], which has in part been ascribed
to the so called "healthy drug-user effect", i.e. that women
using HRT are healthier than average to begin with. Previ-
ous studies of the influence of HRT on breast-cancer char-
acteristics and prognosis have yielded somewhat
conflicting results. Observational studies indicate less
aggressive tumor characteristics in HRT users [5-8,37-42],
while the only randomized study published to date shows
that tumors of HRT users are larger and more likely to
have spread outside the mammary gland [1]. Favorable
tumor characteristics are expected if we assume that HRT
users are under closer surveillance and thus would be
diagnosed earlier in the tumor progression than non-
users. Similarly, improved breast-cancer survival, shown
in some studies [43-45], is also anticipated, although the
specific contribution from surveillance and actual biolog-
ical effects of HRT, respectively, are not readily disentan-
gled. Jernstrom et al, however, showed that survival was
better even after adjusting for stage [45], which supports
the notion that HRT associated tumors are biologically
different.
In line with our findings, no significant difference in
recurrence or survival was seen in a case-control study
when comparing 142 patients with breast cancer using
HRT at time of diagnosis with 284 age-matched patients
not using HRT [39]. ER levels were, however, both quali-
tatively and quantitatively decreased in HRT users. This
finding was replicated in postmenopausal monkeys
(Cynomolgus macaques), where nearly 3 years of exposure
to HRT, including estradiol and progesterone, gave signif-
icantly lower levels of ER in breast tissue [46].
Among the genes most strongly regulated in the HRT- and
non-HRT associated clusters, many were involved in
either DNA repair (e.g. RRM2) or cell-cycle regulation
(e.g. p63). Regulated by p53, RRM2 is essential for DNA
synthesis and repair46. As a p53 homologue, the p63 gene
plays a role in tumor progression and differentiation. In
our study, p63 was over-expressed in HRT associated
tumors and has previously been found to be exclusively
expressed on the protein level in normal breast paren-
chyma, partially expressed in ductal hyperplasia, rarely
expressed in carcinoma in situ, and not expressed in inva-
sive carcinomas [48]. Whether patients with invasive
tumors used HRT at time of diagnosis was not stated.
The non-randomized setting of our study is a major weak-
ness. It could be argued that the ER negativity seen in HRT
users was confounded by their younger age compared
with non-users or by a preferential difficulty to includeBMC Medicine 2006, 4:16 http://www.biomedcentral.com/1741-7015/4/16
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small ER-positive tumors from HRT users (who may be
under closer surveillance and thus diagnosed with smaller
tumors). Reassuringly, the association between gene-
expression profile and survival remained significant after
adjustment for age, stage, and grade. However, factors
related to both HRT use and tumor biology, e.g. level of
endogenous estrogen and receptor proteins or body
weight, would still confound our results. Postmenopausal
breast-cancer risk associated with high body mass index is
largely the result of increase in bioavailable estradiol [49].
However, the increased risk of postmenopausal breast
cancer associated with HRT seems confined to non-obese
women, thus adding complexity to the relationship
between the reason for taking HRT, endogenous factors,
and breast-tumor biology [50]. Furthermore, the small
sample size reduces precision, leaving subtle differences
undetected.
We note in closing that we have not attempted to opti-
mize the 276-gene signature for prediction through the
use of cross-validation, as for example done by Pawitan et
al [17]. The purpose of this study has been entirely explor-
atory, and we use prediction only incidentally to validate
the superior outcome for the HRT-like expression profile;;
the tumor subclasses may have clinical implications, but
the gene signature is not intended as a clinical tool, to
compare these [13].
Despite recent advances in therapy, approximately one-
quarter of all women diagnosed with breast cancer will die
from the disease [51]. Improved targeting of future thera-
pies is thus of utmost importance. Our study provides for
the first time a description of the effect on the tumor gene
expression of HRT use.
Conclusion
HRT alters the expression profiles of ER-positive breast
cancers and patients with an HRT-related expression pro-
file had a better prognosis despite lower ER levels. The
superior prognosis seen with a HRT-associated expression
pattern, also validated in a separate cohort of patients
with breast cancer, remained stable even after adjusting
for Elston grade, lymph node status, progesterone recep-
tor status, tumor size, treatment, and age. The favorable
survival in HRT users seemed to be confined to those
treated with tamoxifen. We speculatively propose that
similarities in gene expression between HRT-exposed
tumors and tamoxifen-treated breast cancer cells may
indicate the mechanism by which the HRT profile is
related to survival.
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